pyrroles has been researched along with tamoxifen in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jonkers, GH | 1 |
| Bland, KI; Filardo, EJ; Frackelton, AR; Quinn, JA | 1 |
| Fresco, P; Gonçalves, J; Pinto, E; Saraiva, L | 1 |
| Evan, GI; Fox, SB; Harris, AL; Knies-Bamforth, UE; Poulsom, R | 1 |
| Boschi, F; D'Onofrio, M; Faccioli, N; Marzola, P; Pozzi Mucelli, R; Sbarbati, A | 1 |
| Boring, D; Grubbs, CJ; Juliana, MM; Lubet, RA; Ruppert, JM; Steele, VE | 1 |
| Baumert, C; Hilgeroth, A | 1 |
| Fargnoli, J; Jordan, VC; Kim, HR; Klein-Szanto, AJ; Li, T; Oseni, S; Patel, RR; Pyle, JR; Ross, EA; Sengupta, S; Zhu, F | 1 |
| Acheampong, A; Ellis, R; Ni, J; Ouyang, H; Rowe, J; Sakuma, T; Seto, C; Szekely-Klepser, G; Welty, D | 1 |
| Askeland, RW; Cyr, AR; Gillum, MP; Spanheimer, PM; Weigel, RJ; Woodfield, GW | 1 |
| Browne, BC; Canonici, A; Crown, J; Ivers, L; Madden, SF; McDermott, MSJ; O'Brien, NA; O'Donovan, N | 1 |
| Chen, X; Deng, H; Huang, H; Ji, S; Jin, W; Shen, J; Shen, Q; Tang, H; Yan, P; Zhang, J; Zhao, X | 1 |
1 review(s) available for pyrroles and tamoxifen
| Article | Year |
|---|---|
Recent advances in the development of P-gp inhibitors.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coumarins; Drug Design; Drug Resistance, Neoplasm; Flavonoids; Humans; Peptides; Propafenone; Propanolamines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Structure-Activity Relationship; Tamoxifen; Terpenes; Verapamil | 2009 |
11 other study(ies) available for pyrroles and tamoxifen
| Article | Year |
|---|---|
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrate; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Middle Aged; Pyrroles; Simvastatin; Tamoxifen; Treatment Outcome | 1999 |
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Topics: Adenylyl Cyclases; Breast Neoplasms; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-raf; Pyrroles; Receptors, Cell Surface; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Tumor Cells, Cultured | 2002 |
Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-alpha, -betaI, -delta, -eta and -zeta.
Topics: Acetophenones; Alkaloids; Animals; Benzophenanthridines; Benzopyrans; Catalysis; Enzyme Inhibitors; Escherichia coli; Indoles; Isoenzymes; Phenanthridines; Piperidines; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein Kinase C-delta; Pyrroles; Saccharomyces cerevisiae; Sphingosine; Tamoxifen; Yeasts | 2003 |
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
Topics: Animals; Cell Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Keratinocytes; Mice; Neovascularization, Physiologic; Oxindoles; Papilloma; Precancerous Conditions; Propionates; Proto-Oncogene Proteins c-myc; Pyrroles; RNA, Messenger; Skin; Skin Neoplasms; Tamoxifen; Transcription Factors; Transgenes; Vascular Endothelial Growth Factor A | 2004 |
Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
Topics: Adenocarcinoma; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Microcirculation; Neoplasms, Experimental; Organometallic Compounds; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Rats; Tamoxifen | 2007 |
Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Atorvastatin; Bexarotene; Cell Proliferation; Diet; Disease Models, Animal; Female; Genes, erbB-2; Heptanoic Acids; Lovastatin; Mammary Neoplasms, Experimental; Methylnitrosourea; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Retinoid X Receptors; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Random Allocation; Receptor, Fibroblast Growth Factor, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transplantation, Heterologous; Triazines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MS.
Topics: Animals; Atorvastatin; Chromatography, Liquid; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Metabolome; Ofloxacin; Omeprazole; Pharmacokinetics; Pyrroles; Rats; Rats, Sprague-Dawley; Tamoxifen; Tandem Mass Spectrometry | 2010 |
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Female; Flow Cytometry; Humans; Indoles; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; MCF-7 Cells; Mice; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Random Allocation; Signal Transduction; Sunitinib; Tamoxifen; Transcription Factor AP-2 | 2014 |
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Somatomedin; Tamoxifen; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
Tamoxifen attenuates dialysate-induced peritoneal fibrosis by inhibiting GSK-3β/β-catenin axis activation.
Topics: Animals; beta Catenin; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Glucose; Glycogen Synthase Kinase 3 beta; Humans; Matrix Metalloproteinase 9; Mice; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Phosphorylation; Pyrimidines; Pyrroles; Snail Family Transcription Factors; Tamoxifen | 2018 |